axitinib
Selected indexed studies
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. (N Engl J Med, 2019) [PMID:30779531]
- Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study. (Ann Oncol, 2024) [PMID:37872020]
- Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study. (Eur Urol, 2023) [PMID:37500340]
_Worker-drafted node — pending editorial review._
Connections
axitinib is a side effect of
Sources
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. (2019) pubmed
- Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study. (2024) pubmed
- Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study. (2023) pubmed
- Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. (2020) pubmed
- Axitinib (AG-013736). (2010) pubmed
- Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial. (2025) pubmed
- Neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus: NEOTAX, a phase 2 study. (2024) pubmed
- Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma. (2021) pubmed
- Axitinib plasma pharmacokinetics and ethnic differences. (2015) pubmed
- Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events. (2020) pubmed